Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CPU0213

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pyrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ-injected…
OBJECTIVES Abnormal vascular activity in diabetes is related not only to impaired nitric oxide bioavailability but also to… Expand
Is this relevant?
2009
2009
Hypercholesterolaemia induces early renal lesions characterized by upregulation of MMP-9 and iNOS and ET(A)R: alleviated by a dual endothelin receptor antagonist CPU0213 and simvastatin.
OBJECTIVES We aimed to investigate hypercholesterolaemia-induced early renal lesions which result in abnormal expression of… Expand
Is this relevant?
2009
2009
Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCε in the heart, which are mitigated by endothelin receptor antagonist CPU0213
AbstractAim:Spatial dispersion of bioactive substances in the myocardium could serve as pathological basis for arrhythmogenesis… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2008
2008
Normalizing NADPH Oxidase Contributes to Attenuating Diabetic Nephropathy by the Dual Endothelin Receptor Antagonist CPU0213 in Rats
Background/Aims: NADPH oxidase(NOX) is the main source of reactive oxygen species (ROS) in diabetic nephropathy (DN). Activation… Expand
  • table 1
Is this relevant?
2008
2008
CPU0213, a novel endothelin receptor antagonist, suppresses the upregulation of matrix metalloproteinases and connexin 43 in hyperthyroid myocardium.
It has been verified that endothelin-1 (ET-1) activates matrix metalloproteinase (MMP) in the process of myocardial remodeling… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon.
Downregulation of FKBP12.6 and sarcoplasmic reticulum Ca(2+) ATPase (SERCA2a) contributes to sudden cardiac death and heart… Expand
Is this relevant?
2007
2007
Upregulated endothelin system in diabetic vascular dysfunction and early retinopathy is reversed by CPU0213 and total triterpene acids from Fructus Corni.
1. The aims of the present study were to examine whether: (i) upregulation of the endothelin (ET) pathway is involved in… Expand
Is this relevant?
2007
2007
Reversal of isoproterenol-induced downregulation of phospholamban and FKBP12.6 by CPU0213-mediated antagonism of endothelin receptors
AbstractAim:The downregulation of phospholamban (PLB) and FKBP12.6 as a result of β-receptor activation is involved in the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2006
2006
A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats.
The depressed sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) and Ca2+-release channels (ryanodine receptor RyR2) are involved… Expand
Is this relevant?
2006
2006
CPU0213, a novel endothelin receptor antagonist, ameliorates septic renal lesion by suppressing ET system and NF-κB in rats
AbstractAim:To examine whether a novel endothelin receptor antagonist, CPU0213, is effective in relieving the acute renal failure… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE